about
Exosomes as a tumor immune escape mechanism: possible therapeutic implicationsThe cancer stem cell: evidence for its origin as an injured autoreactive T cellThe role of CD95 and CD95 ligand in cancerFas-Fas Ligand: Checkpoint of T Cell Functions in Multiple SclerosisThe FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studiesFasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significancesSipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Developing recombinant and synthetic vaccines for the treatment of melanoma.Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.Sipuleucel-T: Prototype for development of anti-tumor vaccines.Blood cells and their use in active immunotherapy of prostate cancer.Immune response to sipuleucel-T in prostate cancerFunctional polymorphisms in FAS, FASL and CASP8 genes and risk of childhood acute lymphoblastic leukemia: a case-control study.Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice.Squamous Cell Carcinoma of the Lower LIP: Fas/Fasl Expression, Lymphocyte Subtypes and Outcome
P2860
Q21245472-FAE4FFE9-8DEF-4A9A-BFB2-B128AD34A96FQ25256839-8A13A9EA-840B-4B24-AF81-720E70E345EBQ26995847-50904694-2A59-40C3-995A-50E2B2AF231AQ28074658-DFAEE8A9-45C8-4322-B595-C09D36650E54Q28384635-23AC79B6-401D-4B96-9651-F95CE05DA5B1Q28385359-5A2D1B44-7709-4EA1-B156-1EDB5E346A0CQ35128716-715D1B23-61A0-4EDD-8894-D86693DCDFD3Q35946196-86180849-87B2-4545-8A9A-B0FC7B65FC05Q35956638-7D016462-CBE0-40A9-A3A7-01D8E4C49D15Q36403535-9FE3FE6C-52DE-4B36-9135-91124324224BQ36432026-09C8F4F3-BF87-4FBA-9046-E1A305A799F6Q37829694-2D5A5053-9996-480C-AEB5-497B279C97F4Q37988722-513C3267-03AF-4CF2-8A9C-ED282DCF8401Q38161390-4EF5022F-B858-4CCF-9791-1CD497B72E8CQ38435201-2054E5A5-3371-4D11-9C7A-5245D893AB45Q44958463-DB38C03C-6857-4026-986E-515FFDD0FAC8Q57765149-6DF9C5A1-70C8-401D-8175-476B361A6511
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
T cell-tumor cell: a fatal interaction?
@ast
T cell-tumor cell: a fatal interaction?
@en
type
label
T cell-tumor cell: a fatal interaction?
@ast
T cell-tumor cell: a fatal interaction?
@en
prefLabel
T cell-tumor cell: a fatal interaction?
@ast
T cell-tumor cell: a fatal interaction?
@en
P2860
P356
P1476
T cell-tumor cell: a fatal interaction?
@en
P2093
D B Chappell
P2860
P2888
P356
10.1007/S002620050505
P577
1998-10-01T00:00:00Z